Breaking News
Investing Pro 0
Cyber Monday SALE: Up to 54% OFF InvestingPro+ CLAIM OFFER
Close

GSK plc DRC (GSKN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
660.00 +0.00    +0.00%
28/10 - Closed. Currency in MXN ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 660.00 - 660.00
Type:  Equity
Market:  Mexico
ISIN:  US37733W1053 
S/N:  37733W105
GSK plc DRC 660.00 +0.00 +0.00%

GSKN Income Statement

 
Assess the GlaxoSmithKline income statement, view the company's financial performance across their assets and liabilities. Select to view either quarterly or annual data.
AnnualQuarterly
InvestingPro Advanced Income Statement
Period Ending: 2022
30/09
2022
30/06
2022
31/03
2021
31/12
Total Revenue 7829 6929 7190 -
Revenue 7829 6929 7190 -
Other Revenue, Total - - - -
Cost of Revenue, Total 2386 2145 2690 -
Gross Profit 5443 4784 4500 -
Total Operating Expenses 5468 5220 5482 -
Selling/General/Admin. Expenses, Total 2014 1960 1783 -
Research & Development 1323 1180 1112 -
Depreciation / Amortization 758 - 507 -
Interest Expense (Income) - Net Operating -199 -204 -205 -
Unusual Expense (Income) - - - -
Other Operating Expenses, Total -814 139 -405 -
Operating Income 2361 1709 1708 -
Interest Income (Expense), Net Non-Operating - - - -
Gain (Loss) on Sale of Assets - - - -
Other, Net 1349 813 -386 -
Net Income Before Taxes 1012 896 2094 -
Provision for Income Taxes 233 150 323 -
Net Income After Taxes 779 746 1771 -
Minority Interest -436 6266 6451 6287
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 759 706 1496 -
Total Extraordinary Items 9556 132 306 -
Net Income 10315 838 1802 -
Total Adjustments to Net Income -9556 -132 -306 -
Income Available to Common Excluding Extraordinary Items 759 706 1496 -
Dilution Adjustment 9554.63 130.86 305.1 -
Diluted Net Income 760.37 707.14 1496.9 -
Diluted Weighted Average Shares 4088 4064 4054 -
Diluted EPS Excluding Extraordinary Items 0.186 0.174 0.369 -
DPS - Common Stock Primary Issue 0.138 0.162 0.175 -
Diluted Normalized EPS 0.329 0.225 0.165 -
* In Millions of (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GSK Comments

Write your thoughts about Glaxosmithkline
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Oc Masai
Oc Masai Apr 27, 2021 7:51
Saved. See Saved Items.
This comment has already been saved in your Saved Items
GSK movie forward. Thanks you
Faruk Mia
Faruk Mia Apr 27, 2021 7:51
Saved. See Saved Items.
This comment has already been saved in your Saved Items
হাই
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email